omeprazole has been researched along with Laryngeal Diseases in 21 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Laryngeal Diseases: Pathological processes involving any part of the LARYNX which coordinates many functions such as voice production, breathing, swallowing, and coughing.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients with symptoms suspected to be due to laryngopharyngeal reflux (based on a positive oesophageal pH test and/or changes on videolaryngoscopy consistent with posterior laryngitis) were treated with omeprazole for at least two to three months." | 3.70 | Presumed laryngo-pharyngeal reflux: investigate or treat? ( Fraser, AG; Gillibrand, J; Morton, RP, 2000) |
| "Treatment with omeprazole significantly improved QL in both LPR subgroups patients." | 2.73 | Quality of life in laryngopharyngeal reflux patients. ( Adamonis, K; Siupsinskiene, N; Toohill, RJ, 2007) |
| "All omeprazole-treated patients showed improvement of laryngeal features and symptoms." | 2.72 | Silent reflux: ex juvantibus criteria for diagnosis and treatment of laryngeal disorders. ( Barbara, M; Di Stadio, A; Monini, S; Vestri, A, 2006) |
| "Gastroesophageal reflux (GER) can cause serious voice problems and laryngopharyngeal disorders influencing the patient's quality of life." | 1.33 | Voice disorders and gastroesophageal reflux. ( Hocevar-Boltezar, I; Jansa, R; Sereg-Bahar, M, 2005) |
| "Idiopathic hoarseness as a single symptom increases the odds ratio for laryngopharyngeal reflux disease 85 times." | 1.31 | [Typical and atypical symptoms of laryngopharyngeal reflux disease]. ( Jonaitis, L; Pribuisiene, R; Uloza, V, 2002) |
| " Results were further analyzed to compare failure rates based on different dosage regimens." | 1.31 | Proton pump inhibitor resistance in the treatment of laryngopharyngeal reflux. ( Amin, MR; Digges, N; Johnson, P; Koufman, JA; Postma, GN, 2001) |
| "Gastroesophageal reflux, common in infants, usually resolves spontaneously by 12 to 18 months." | 1.31 | [Laryngeal manifestations of gastroesophageal reflux disease (GERD) in pediatric patients: the usefulness of therapeutic (proton pump inhibitor (PPI)) trials]. ( Niimi, S; Saigusa, H; Saigusa, U; Yagi, T, 2001) |
| "Although the association between gastroesophageal reflux disease (GERD) and laryngeal disorders in adults is well established there is still a lack of information concerning the true extent of the laryngeal complications of GERD in children." | 1.31 | Laryngeal manifestations of gastroesophageal reflux disease in children. ( Blitek, A; Horobiowska, M; Iwanczak, B; Krecicki, T; Zalesska-Krecicka, M, 2002) |
| "The association between GERD and these supraesophageal symptoms may be elusive." | 1.30 | Supraesophageal manifestations of gastroesophageal reflux disease. ( Al-Sabbagh, G; Wo, JM, 1999) |
| "Those ascribed to gastroesophageal reflux and vocal abuse have a high resolution rate, although some cases need rescue procedures." | 1.30 | Clinical evolution of laryngeal granulomas: treatment and prognosis. ( De Biase, NG; de Lima Pontes, PA; Gadelha, EC, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 16 (76.19) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pribuisiene, R | 1 |
| Uloza, V | 1 |
| Jonaitis, L | 1 |
| Scheid, SC | 1 |
| Anderson, TD | 1 |
| Sataloff, RT | 1 |
| Hill, RK | 1 |
| Simpson, CB | 1 |
| Velazquez, R | 1 |
| Larson, N | 1 |
| Carrau, RL | 1 |
| Khidr, A | 1 |
| Gold, KF | 1 |
| Crawley, JA | 1 |
| Hillson, EM | 1 |
| Koufman, JA | 3 |
| Pashos, CL | 1 |
| Sereg-Bahar, M | 1 |
| Jansa, R | 1 |
| Hocevar-Boltezar, I | 1 |
| Stavroulaki, P | 1 |
| Silvers, WS | 1 |
| Levine, JS | 1 |
| Poole, JA | 1 |
| Naar, E | 1 |
| Weber, RW | 1 |
| Ludemann, JP | 1 |
| Kozak, FK | 1 |
| Monini, S | 1 |
| Di Stadio, A | 1 |
| Vestri, A | 1 |
| Barbara, M | 1 |
| Garcia, I | 1 |
| Krishna, P | 1 |
| Rosen, CA | 1 |
| Siupsinskiene, N | 1 |
| Adamonis, K | 1 |
| Toohill, RJ | 1 |
| Richter, JE | 1 |
| Hicks, DM | 1 |
| de Caestecker, J | 1 |
| Al-Sabbagh, G | 1 |
| Wo, JM | 1 |
| Emami, AJ | 1 |
| Morrison, M | 1 |
| Rammage, L | 1 |
| Bosch, D | 1 |
| de Lima Pontes, PA | 1 |
| De Biase, NG | 1 |
| Gadelha, EC | 1 |
| Fraser, AG | 1 |
| Morton, RP | 1 |
| Gillibrand, J | 1 |
| Belafsky, PC | 1 |
| Postma, GN | 2 |
| Amin, MR | 1 |
| Johnson, P | 1 |
| Digges, N | 1 |
| Saigusa, H | 1 |
| Niimi, S | 1 |
| Saigusa, U | 1 |
| Yagi, T | 1 |
| Zalesska-Krecicka, M | 1 |
| Krecicki, T | 1 |
| Iwanczak, B | 1 |
| Blitek, A | 1 |
| Horobiowska, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Care For Infants With Laryngomalacia: A Pilot Randomized Controlled Trial of Omeprazole Versus Placebo[NCT01782560] | Phase 1 | 0 participants (Actual) | Interventional | 2013-02-28 | Withdrawn (stopped due to Unable to recruit a sufficient amount of subjects) | ||
| A Randomized Controlled Trial Comparing Proton Pump Inhibitor Therapy With and Without Interarytenoid Botulinum Toxin Injection for Vocal Fold Granuloma[NCT01678053] | Phase 2 | 0 participants (Actual) | Interventional | 2012-09-30 | Withdrawn (stopped due to Was not able to recruit patients for randomization.) | ||
| A Randomized, Placebo-Controlled Assessment of Lansoprazole 30 mg Bid in the Treatment of Gastroesophageal Reflux Associated With Laryngitis[NCT00369265] | Phase 4 | 18 participants (Actual) | Interventional | 2006-08-31 | Terminated (stopped due to Pharmaceutical company purchased by another company and funding was terminated.) | ||
| A Prospective Evaluation of the Utility, Optimal Cutoff and Positive Predictive Value of a Pharyngeal pH Probe for Predicting Proton Pump Inhibitor Response in Treatment Naive Laryngopharyngeal Reflux[NCT01755221] | 80 participants (Anticipated) | Interventional | 2012-08-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for omeprazole and Laryngeal Diseases
| Article | Year |
|---|---|
Diagnostic and management problems of laryngopharyngeal reflux disease in children.
Topics: Child; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Infant; Laryngeal Diseases; L | 2006 |
Medical therapy for supraesophageal complications of gastroesophageal reflux.
Topics: Clinical Trials as Topic; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Laryngeal Disea | 1997 |
2 trials available for omeprazole and Laryngeal Diseases
| Article | Year |
|---|---|
Silent reflux: ex juvantibus criteria for diagnosis and treatment of laryngeal disorders.
Topics: Adjuvants, Immunologic; Administration, Oral; Administration, Sublingual; Adult; Aged; Aged, 80 and | 2006 |
Quality of life in laryngopharyngeal reflux patients.
Topics: Adult; Enzyme Inhibitors; Female; Follow-Up Studies; Gastroesophageal Reflux; Humans; Laryngeal Dise | 2007 |
17 other studies available for omeprazole and Laryngeal Diseases
| Article | Year |
|---|---|
[Typical and atypical symptoms of laryngopharyngeal reflux disease].
Topics: Adult; Anti-Ulcer Agents; Diagnosis, Differential; Esophagus; Female; Gastroesophageal Reflux; Heart | 2002 |
Nonoperative treatment of laryngeal granuloma.
Topics: Anti-Ulcer Agents; Gastroesophageal Reflux; Granuloma; Humans; Laryngeal Diseases; Laryngoscopy; Mal | 2003 |
Pachydermia is not diagnostic of active laryngopharyngeal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2004 |
Validation of a quality-of-life instrument for laryngopharyngeal reflux.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Humans; Laryngeal Diseases; Middle Aged; Omeprazo | 2005 |
Voice disorders and gastroesophageal reflux.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Enzyme Inhibitors; Esophagoscopy; Female; Gastroesoph | 2005 |
Inlet patch of gastric mucosa in upper esophagus causing chronic cough and vocal cord dysfunction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Androstadienes; Anti-Allergic Agents; Cough; Endoscopy, Gas | 2006 |
Letter to the Editor regarding pediatric postcricoid masses.
Topics: Anti-Ulcer Agents; Child; Cricoid Cartilage; Humans; Laryngeal Diseases; Laryngoscopy; Omeprazole; P | 2006 |
Severe laryngeal hyperkeratosis secondaryto laryngopharyngeal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Therapy, Combination; Gastroesophageal | 2006 |
Unresolved issues in gastroesophageal reflux-related ear, nose, and throat problems.
Topics: Animals; Anti-Ulcer Agents; Esophagus; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion C | 1997 |
Supraesophageal manifestations of gastroesophageal reflux disease.
Topics: Adult; Anti-Ulcer Agents; Cough; Domperidone; Dopamine Antagonists; Endoscopy, Gastrointestinal; Fem | 1999 |
Treatment of laryngeal contact ulcers and granulomas: a 12-year retrospective analysis.
Topics: Adult; Aged; Anti-Ulcer Agents; Botulinum Toxins, Type A; Female; Granuloma; Humans; Laryngeal Disea | 1999 |
Clinical evolution of laryngeal granulomas: treatment and prognosis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Antiemetics; Botulinum Toxins, Type A; Combined Modality | 1999 |
Presumed laryngo-pharyngeal reflux: investigate or treat?
Topics: Anti-Ulcer Agents; Clinical Protocols; Diagnosis, Differential; Female; Gastroesophageal Reflux; Hum | 2000 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Proton pump inhibitor resistance in the treatment of laryngopharyngeal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; | 2001 |
[Laryngeal manifestations of gastroesophageal reflux disease (GERD) in pediatric patients: the usefulness of therapeutic (proton pump inhibitor (PPI)) trials].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Gastroesophageal Reflux; Humans; I | 2001 |
Laryngeal manifestations of gastroesophageal reflux disease in children.
Topics: Child; Enzyme Inhibitors; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Laryn | 2002 |